Interaction of the antibiotic sparsomycin with the ribosome. 1991

E Lazaro, and A San Felix, and L A van den Broek, and H C Ottenheijm, and J P Ballesta
Centro de Biología Molecular, Universidad Autónoma, Madrid, Spain.

Phenol-alanine-sparsomycin, a derivative of sparsomycin carrying a p-hydroxy-benzyl function easily labeled by iodination, has been used to study the interaction of this drug with the ribosome. Our study indicated that the binding of the drug to the ribosome is sensitive to trichloracetic acid and is equally affected by disintegration of the particle after RNase and protease treatments. The ribosome is not irreversibly inactivated, and the chemical structure of the drug is not affected by interaction with the particle. These data are not compatible with the proposed covalent association of sparsomycin with the ribosome by G. A. Flynn and R. J. Ash (Biochem. Biophys. Res. Commun. 114:1-7, 1983); therefore, the antibiotic must inhibit protein synthesis through a reversible interaction with the ribosome.

UI MeSH Term Description Entries
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D012270 Ribosomes Multicomponent ribonucleoprotein structures found in the CYTOPLASM of all cells, and in MITOCHONDRIA, and PLASTIDS. They function in PROTEIN BIOSYNTHESIS via GENETIC TRANSLATION. Ribosome
D013033 Sparsomycin An antitumor antibiotic produced by Streptomyces sparsogenes. It inhibits protein synthesis in 70S and 80S ribosomal systems.

Related Publications

E Lazaro, and A San Felix, and L A van den Broek, and H C Ottenheijm, and J P Ballesta
April 1969, Nature,
E Lazaro, and A San Felix, and L A van den Broek, and H C Ottenheijm, and J P Ballesta
February 2003, Current opinion in investigational drugs (London, England : 2000),
E Lazaro, and A San Felix, and L A van den Broek, and H C Ottenheijm, and J P Ballesta
March 1977, Journal of medicinal chemistry,
E Lazaro, and A San Felix, and L A van den Broek, and H C Ottenheijm, and J P Ballesta
July 2010, The journal of physical chemistry. B,
E Lazaro, and A San Felix, and L A van den Broek, and H C Ottenheijm, and J P Ballesta
March 1980, Biochemistry,
E Lazaro, and A San Felix, and L A van den Broek, and H C Ottenheijm, and J P Ballesta
January 1988, Anticancer research,
E Lazaro, and A San Felix, and L A van den Broek, and H C Ottenheijm, and J P Ballesta
February 1990, Investigational new drugs,
E Lazaro, and A San Felix, and L A van den Broek, and H C Ottenheijm, and J P Ballesta
January 1986, Progress in medicinal chemistry,
E Lazaro, and A San Felix, and L A van den Broek, and H C Ottenheijm, and J P Ballesta
August 1999, Proceedings of the National Academy of Sciences of the United States of America,
E Lazaro, and A San Felix, and L A van den Broek, and H C Ottenheijm, and J P Ballesta
March 2001, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!